Evidence map›Paper›PMID 27899227›Full record

ArticleVaccine2017

Challenges to estimating vaccine impact using hospitalization data.

Cynthia Schuck-Paim, Robert J Taylor, Lone Simonsen, Roger Lustig, Esra Kürüm, Christian A W Bruhn, Daniel M Weinberger

Abstract read
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cynthia Schuck-PaimSage Analytica, Portland, ME, United States. Electronic address: cschuck@sageanalytica.com.
Robert J TaylorSage Analytica, Portland, ME, United States.
Lone SimonsenDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, United States.
Roger LustigSage Analytica, Portland, ME, United States.
Esra KürümDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States; Department of Statistics, University of California, Riverside, CA, United States.
Christian A W BruhnDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States.
Daniel M WeinbergerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States.

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Denise Esserman · 2002 to 2026
$37.9M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Global Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2M
Forecasting pneumococcal serotype frequencies to develop adult-specific vaccinesR01AI123208 · NIAID · YALE UNIVERSITY · PI WEINBERGER, DANIEL MARTIN · 2016 to 2019
$2.5M
Forecasting pneumococcal serotype frequencies to develop adult-specific vaccinesR56AI110449 · NIAID · YALE UNIVERSITY · PI WEINBERGER, DANIEL MARTIN · 2015 to 2015
$427k
FIC NIH HHS D43 TW010540FIC NIH HHS R25 TW009338NCATS NIH HHS UL1 TR000142NIAID NIH HHS R01 AI123208NIAID NIH HHS R56 AI110449NIA NIH HHS P30 AG021342
6 · The paper itself

Abstract

Because the real-world impact of new vaccines cannot be known before they are implemented in national programs, post-implementation studies at the population level are critical. Studies based on analysis of hospitalization rates of vaccine-preventable outcomes are typically used for this purpose. However, estimates of vaccine impact based on hospitalization data are particularly prone to confounding, as hospitalization rates are tightly linked to changes in the quality, access and use of the healthcare system, which often occur simultaneously with introduction of new vaccines. Here we illustrate how changes in healthcare delivery coincident with vaccine introduction can influence estimates of vaccine impact, using as an example reductions in infant pneumonia hospitalizations after introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) in Brazil. To this end, we explore the effect of changes in several metrics of quality and access to public healthcare on trends in hospitalization rates before (2008-09) and after (2011-12) PCV10 introduction in 2010. Changes in infant pneumonia hospitalization rates following vaccine introduction were significantly associated with concomitant changes in hospital capacity and the fraction of the population using public hospitals. Importantly, reduction of pneumonia hospitalization rates after PCV10 were also associated with the expansion of outpatient services in several Brazilian states, falling more sharply where primary care coverage and the number of health units offering basic and emergency care increased more. We show that adjustments for unrelated (non-vaccine) trends commonly employed by impact studies, such as use of single control outcomes, are not always sufficient for accurate impact assessment. We discuss several ways to identify and overcome such biases, including sensitivity analyses using different denominators to calculate hospitalizations rates and methods that track changes in the outpatient setting. Employing these practices can improve the accuracy of vaccine impact estimates, particularly in evolving healthcare settings typical of low- and middle-income countries.

Indexed as

HospitalizationBiostatisticsBrazilFemaleHumansInfantMalePneumococcal VaccinesPneumonia, PneumococcalTreatment Outcome10-valent pneumococcal conjugate vaccinePneumococcal VaccinesBiasBrazilConfounding factorsDelivery of health careHealth impact assessmentHospitalizationLatin AmericaObservational studiesPneumococcal conjugate vaccinesPneumococcal vaccinesPneumococcusPneumoniaPublic healthVaccines

Identifiers

PMID27899227
PMCPMC5664940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.